Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Novavax Inc. closed 69.87% short of its 52-week high of $23.86, which the company reached on June 6th.

Shares of Novavax Inc. NVAX slid 6.23% to $6.92 Wednesday, on what proved to be an all-around grim trading session for the ...

User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...

Novavax's shot is now fully approved in the U.S. Since 2022, the vaccine has been used under an emergency use authorization.

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The U.S. Food and Drug Administration (FDA) has granted full approval to Novavax's COVID-19 vaccine, but only for certain ...